Form D · Biotechnology
Morphoceuticals, Inc.
Medford, MA · CIK 0001962989
Offering snapshot reported Oct 7, 2024 · SEC filing
- Reported sold
- $3.5M Offering amount: $5.5M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 23, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 7, 2024 | Initial | $3,500,000 | No comparison | 1 | SEC filing |
| Jan 23, 2023 | Initial | $9,820,000 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-526068
Source: Form D, filed Oct 7, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Tamim Hamad J.J Al Thani | Director |
| Justin Briggs | Director |
| David Gill | Executive |
| Michael R. Hufford | Director |
| Rosemarie Hunziker | Director |
| James Jenson | Director, Executive |
| David Kaplan | Promoter |
| Amy Kruse | Director |
| Michael Levin | Promoter |
| Alexander Pickett | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
200 Boston Avenue Suite G 725
Medford, MA, 02155
Medford, MA, 02155